Spravato (Esketamine) Raising Both Hopes and Concerns
Many of you may or may not have heard that Spravato (Esketamine), a nasal spray, was approved by the US FDA in March of 2019 for treatment-resistant depression. This new drug is a ketamine cousin since it is a portion of the ketamine molecule. It has been touted as a breakthrough in the treatment of depression. I think the jury is still out. There are many things about Spravato that may be beneficial, but there is a lot we do not know. The patient treatment course is long and difficult with 2 treatments per week for 1 month, and 1 treatment per week for a month following the initial month of treatment. Those treatments are required to be given in an office with an observation period of 2 hours for each treatment. Janssen, the makers of Spravato, did perform clinical trials but again I think the jury is still out. I think there is more evidence to support the use of intravenous ketamine as a treatment for depression at this time. As a member of the ASKP (American Society of Ketamine Physicians), I have attended conferences and webinars with leaders in the field of ketamine. I have heard the stories of their successes. I have seen my own patients turn their lives around after receiving intravenous ketamine therapy for depression. If you have questions about ketamine, give us a call. The team at Thrive is here to help. We want you to flourish without restrictions.